EFG Asset Management Americas Corp. Buys 2,175 Shares of Danaher Corporation $DHR

EFG Asset Management Americas Corp. raised its position in shares of Danaher Corporation (NYSE:DHR) by 6.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,255 shares of the conglomerate’s stock after purchasing an additional 2,175 shares during the quarter. Danaher accounts for about 1.4% of EFG Asset Management Americas Corp.’s investment portfolio, making the stock its 17th largest position. EFG Asset Management Americas Corp.’s holdings in Danaher were worth $7,557,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of DHR. Pacific Capital Partners Ltd purchased a new stake in shares of Danaher during the first quarter worth about $7,175,000. Proficio Capital Partners LLC boosted its stake in Danaher by 3.2% in the 1st quarter. Proficio Capital Partners LLC now owns 2,647 shares of the conglomerate’s stock worth $543,000 after purchasing an additional 81 shares during the period. Oak Thistle LLC purchased a new stake in Danaher during the 1st quarter valued at approximately $2,904,000. SYM FINANCIAL Corp bought a new stake in shares of Danaher during the first quarter valued at approximately $311,000. Finally, Kidder Stephen W boosted its position in shares of Danaher by 0.9% during the first quarter. Kidder Stephen W now owns 36,583 shares of the conglomerate’s stock worth $7,500,000 after acquiring an additional 314 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $222.58 on Thursday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average price of $207.29 and a 200-day moving average price of $201.61. The firm has a market capitalization of $157.22 billion, a PE ratio of 45.89, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.71 EPS. As a group, equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. This represents a 13.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,026 shares of company stock worth $7,195,987 in the last quarter. 11.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on DHR shares. Wall Street Zen downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Monday, November 10th. Cowen reaffirmed a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Rothschild Redb downgraded shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.